Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 12, 2012, Pages

  Rojas, Jennifer M ^a,b   Stafford, John M ^a,b   Saadat, Sanaz ^b   Printz, Richard L ^a,b   Beck Sickinger, Annette G ^c   Niswender, Kevin D ^a,b  

^a Tennessee Valley Healthcare System   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Brain; Hepatic lipid metabolism; Obesity dyslipidemia

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY FAT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENERGY BALANCE; FEEDING BEHAVIOR; FOOD INTAKE; HYPERPHAGIA; HYPERTRIGLYCERIDEMIA; LEAN BODY WEIGHT; LIPOLYSIS; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APPETITE REGULATION; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; HUMANS; HYPERPHAGIA; INFUSIONS, INTRAVENTRICULAR; LIPOPROTEINS, VLDL; LIVER; MALE; NERVE TISSUE PROTEINS; NEURONS; NEUROPEPTIDE Y; OBESITY; PROTEIN ISOFORMS; RATS; RATS, LONG-EVANS; RECEPTORS, NEUROPEPTIDE Y; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84871298918     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00351.2012     Document Type: Article

References (71)

1. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 1225-1236, 2008.
2. Balasubramaniam A, Joshi R, Su C, Friend LA, James JH. Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists. Peptides 28: 235-240, 2007.
3. Balasubramaniam A, Sheriff S, Zhai W, Chance WT. Bis(31/ 31=){[Cys(31), Nva(34)]NPY(27-36)-NH(2)}: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides 23: 1485-1490, 2002.
4. Baranowska B, Wolínska-Witort, E, Martýnska, L, Chmielowska, M, Mazurczak-Pluta, T, Boguradzka, A, Baranowska-Bik, A. Sibutramine therapy in obese women-effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol Lett 26: 675-679, 2005.
5. Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, Roguski K, Martynska L, Chmielowska M. The role of neuropeptides in the disturbed control of appetite and hormone secretion in eating disorders. Neuro Endocrinol Lett 24: 431-434, 2003.
6. Barrows BR, Parks EJ. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 91: 1446-1452, 2006.
7. Bartels ED, Lauritsen M, Nielsen LB. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51: 1233-1239, 2002.
8. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.
9. Beck B, Burlet A, Bazin R, Nicolas JP, Burlet C. Elevated neuropeptide Y in the arcuate nucleus of young obese Zucker rats may contribute to the development of their overeating. J Nutr 123: 1168-1172, 1993.
10. Bernardis LL, Schnatz JD. Localization in the ventromdedial hypothalamic nuclei of an area affecting plasma triglyceride and cholesterol levels. J Neurovisc Relat 32: 90-103, 1971.
11. Blumenthal JB, Andersen RE, Mitchell BD, Seibert MJ, Yang H, Herzog H, Beamer BA, Franckowiak SC, Walston JD. Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride and high-density lipoprotein cholesterol levels. Clin Genet 62: 196-202, 2002.
12. Bruinstroop E, Pei L, Ackermans MT, Foppen E, Borgers AJ, Kwakkel J, Alkemade A, Fliers E, Kalsbeek A. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 61: 1043-1050, 2012.
13. Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O, Beck-Sickinger AG. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem 275: 36043-36048, 2000.
14. Cartwright IJ, Higgins JA. Quantification of apolipoprotein B-48 and B-100 in rat liver endoplasmic reticulum and Golgi fractions. Biochem J 285: 153-159, 1992.
15. Chee MJ, Myers MG Jr, Price CJ, Colmers WF Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus. J Neurosci 30: 3380-3390, 2010.
16. Cleary MP, Vasselli JR, Greenwood MR. Development of obesity in Zucker obese (fafa) rat in absence of hyperphagia. Am J Physiol Endocrinol Metab 238: E284-E292, 1980.
17. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297: 240-243, 2002.
18. Fetissov SO, Kopp J, Hokfelt T. Distribution of NPY receptors in the hypothalamus. Neuropeptides 38: 175-188, 2004.
19. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277: 17377-17380, 2002.
20. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 31: 642-648, 2010.
21. Ghamari-Langroudi M, Colmers WF, Cone RD. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab 2: 191-199, 2005.
22. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 106: 453-458, 2000.
23. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14, Suppl 1: 41S-49S, 2006.
24. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 293: 1868-1874, 2005.
25. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546, 1995.
26. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
27. Iyengar S, Li DL, Simmons RM. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding? J Pharmacol Exp Ther 289: 1031-1040, 1999.
28. Jang M, Romsos DR. Neuropeptide Y and corticotropin-releasing hormone concentrations within specific hypothalamic regions of lean but not ob/ob mice respond to food-deprivation and refeeding. J Nutr 128: 2520-2525, 1998.
29. Kamiji MM, Inui A. Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev 28: 664-684, 2007.
30. Karakash C, Hustvedt BE, Lovo A, Le Marchand Y, Jeanrenaud B. Consequences of ventromedial hypothalamic lesions on metabolism of perfused rat liver. Am J Physiol Endocrinol Metab Gastrointest Physiol 232: E286-E293, 1977.
31. Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolic syndrome. Dis Model Mech 3: 156-166, 2010.
32. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 12: 563-571, 1976.
33. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13: 803-811, 2007.
34. Lam TK, Gutierrez-Juarez R, Pocai A, Bhanot S, Tso P, Schwartz GJ, Rossetti L. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med 13: 171-180, 2007.
35. Lindner D, Stichel J, Beck-Sickinger AG. Molecular recognition of the NPY hormone family by their receptors. Nutrition 24: 907-917, 2008.
36. Marks JL, Waite K. Intracerebroventricular neuropeptide Y acutely influences glucose metabolism and insulin sensitivity in the rat. J Neuroendocrinol 9: 99-103, 1997.
37. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4: 718-721, 1998.
38. Merten N, Lindner D, Rabe N, Römpler H, Mörl K, Schöneberg T, Beck-Sickinger AG. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine residues in Y receptor ligands. J Biol Chem 282: 7543-7551, 2007.
39. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195-1200, 2001.
40. Niswender KD, Morrison CD, Clegg DJ, Olson R, Baskin DG, Myers MG Jr, Seeley RJ, Schwartz MW. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 52: 227-231, 2003.
41. Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howles PN, Morgan DA, Benoit SC, Szanto I, Schrott B, Schürmann A, Joost HG, Hammond C, Hui DY, Woods SC, Rahmouni K, Butler AA, Farooqi IS, O'Rahilly S, Rohner-Jeanrenaud F, Tschöp MH. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 117: 3475-3488, 2007.
42. Otway S, Robinson DS. The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol 190: 321-332, 1967.
43. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13: 18-19, 1996.
44. Picardi PK, Calegari VC, Prada Pde O, Moraes JC, Araújo E, Marcondes MC, Ueno M, Carvalheira JB, Velloso LA, Saad MJ. Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats. Endocrinology 149: 3870-3880, 2008.
45. Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A, Pennathur S, Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296: E1003-E1012, 2009.
46. Pralong FP, Gonzales C, Voirol MJ, Palmiter RD, Brunner HR, Gaillard RC, Seydoux J, Pedrazzini T. The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions. FASEB J 16: 712-714, 2002.
47. Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. Endocrinology 140: 4046-4055, 1999.
48. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 185: 195-204, 2001.
49. Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 22: 414-423, 1998.
50. Rioux KP, Le T, Swain MG. Decreased orexigenic response to neuropeptide Y in rats with obstructive cholestasis. Am J Physiol Gastrointest Liver Physiol 280: G449-G456, 2001.
51. Rojas JM, Printz RL, Niswender KD. Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats. Nutr Diab 1: e10, 2011.
52. Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 51: 3420-3427, 2002.
53. Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ, Herzog H. Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev 16: 1077-1088, 2002.
54. Sanacora G, Kershaw M, Finkelstein JA, White JD. Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation. Endocrinology 127: 730-737, 1990.
55. Schotz MC, Scanu A, Page IH. Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol 188: 399-402, 1957.
56. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 45: 531-535, 1996.
57. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44: 147-151, 1995.
58. Söll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 268: 2828-2837, 2001.
59. Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 57: 1482-1490, 2008.
60. Staníc D, Mulder J, Watanabe M, Hökfelt T. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules. J Comp Neurol 519: 1219-1257, 2011.
61. Swift LL. Role of the Golgi apparatus in the phosphorylation of apolipoprotein B. J Biol Chem 271: 31491-31495, 1996.
62. Tschöp M, Castañeda TR, Joost HG, Thöne-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 1, 2004.
63. van den Hoek AM, van Heijningen C, Schroder-van der Elst JP, Ouwens DM, Havekes LM, Romijn JA, Kalsbeek A, Pijl H. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes 57: 2304-2310, 2008.
64. van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, Pijl H. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 53: 2529-2534, 2004.
65. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37: 1202-1208, 1994.
66. Warne JP, Alemi F, Reed AS, Varonin JM, Chan H, Piper ML, Mullin ME, Myers MG Jr, Corvera CU, Xu AW. Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity. Cell Metab 14: 791-803, 2011.
67. Wiedmer P, Chaudhary N, Rath M, Yi CX, Ananthakrishnan G, Nogueiras R, Wirth EK, Kirchner H, Schweizer U, Jonas W, Veyrat-Durebex C, Rohner-Jeanrenaud F, Schürmann A, Joost HG, Tschöp MH, Perez-Tilve D. The HPA axis modulates the CNS melanocortin control of liver triacylglyceride metabolism. Physiol Behav 105: 791-799, 2012.
68. Wilding JP, Gilbey SG, Mannan M, Aslam N, Ghatei MA, Bloom SR. Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. J Endocrinol 132: 299-304, 1992.
69. Wyss P, Stricker-Krongrad A, Brunner L, Miller J, Crossthwaite A, Whitebread S, Criscione L. The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 75-76: 363-371, 1998.
70. Yue JT, Mighiu PI, Naples M, Adeli K, Lam TK. Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats. Circ Res 110: 1345-1354, 2012.
71. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.